Personalis, Inc. (PSNL) Stock Score, Valuation & Financial Research

Personalis, Inc. is in the Healthcare sector and Medical - Diagnostics & Research industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 24/100.

Quick answer for PSNL

Personalis, Inc. currently has a Wall Street Score of 24/100. The stored market price is USD 15.90. Its financial score is 25/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.

What Personalis, Inc. does

Personalis, Inc. operates globally as a specialized cancer genomics firm. The company delivers advanced sequencing and data analysis capabilities, primarily supporting the development of novel cancer treatments and facilitating extensive genetic research initiatives. Central to their offerings is the NeXT Platform, which enables detailed data analysis of tumors and their surrounding immune microenvironments, even from small tissue or plasma samples. This platform encompasses several specialized solutions: ImmunoID Next for tissue-based tumor profiling; NeXT Liquid Biopsy for plasma analysis; NeXT Personal, a specific liquid biopsy designed for individual patient tumor tracking; the NeXT Dx Test, a genomic cancer profiling tool that identifies composite biomarkers for treatment guidance; and the sophisticated NeXT SHERPA and NeXT NEOPS for predicting neoantigens. Additionally, Personalis offers the ACE platform, utilized for diverse clinical and therapeutic applications like neoantigen prediction, biomarker identification, and the selection of new drug targets. Their clientele includes biopharmaceutical companies, academic institutions, non-profit organizations, and government entities. The company has established significant partnerships with organizations such as Mayo Clinic, MapKure, LLC, SpringWorks Therapeutics, Inc., and Moores Cancer Center. Personalis, Inc. was founded in 2011 and is based in Menlo Park, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Personalis generates revenue primarily by providing advanced genomic sequencing and analytics services to biopharmaceutical companies for clinical trials and research, and by offering clinical diagnostic tests to healthcare providers. The company operates a laboratory-based business model where it processes patient samples to provide insights into cancer genomics, relying on reimbursement from Medicare and other payers for its clinical diagnostic offerings.

Products and services

The company provides cancer genomic testing services, including the NeXT Personal Dx test for minimal residual disease (MRD) detection and surveillance, and various sequencing and data analysis services for biopharmaceutical research.

Brands and product families

NeXT Personal Dx — The company's primary clinical diagnostic test for minimal residual disease detection. Source

Customer types

Biopharmaceutical companies; Healthcare providers; Government entities.

Disclosed major customers

Moderna Source
VA MVP Source
Natera Source

Suppliers, materials and equipment

Laboratory supplies and consumables providers — Unnamed suppliers of laboratory reagents, sequencing equipment, and related consumables. Source

Business relationships and partnerships

Tempus AI, Inc. — A commercial collaboration to market and commercialize the NeXT Personal Dx test in the clinical diagnostics market. Source

Competitors and product-market comparisons

Natera — Competes in the MRD testing and cancer diagnostics market. Source

Business strengths to evaluate

Proprietary ultrasensitive MRD detection technology Source
Medicare coverage for NeXT Personal Dx Source

Business risks and research considerations

High customer concentration and reliance on a limited number of large customers Source
Uncertainty regarding reimbursement coverage and medical necessity for diagnostic tests Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

Financial risk observations and what to check

These are saved observations about business performance, not predictions. Review the company filings alongside the interpretation below. Latest stored financial period end: 2026-06-30.

Diluted weighted-average shares increased 19.1% year over year. Compare per-share results with total earnings and inspect the equity footnote. A change in weighted-average shares does not by itself establish the cause, the number of shares issued today, or the economic effect of a split.

PSNL financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:: 24/100
Stored price:: USD 15.90
Market capitalization:: 1.7B (currency not supplied)
Revenue:: USD 69.67M
Net income:: USD -107.18M
Free cash flow:: USD -79.45M
Cash:: USD 93.97M
Total debt:: USD 38M
EPS:: USD -1.09
Financial score:: 25/100
Valuation score:: 0/100
Revenue score:: 0/100

What stands out

Reported year-over-year revenue growth is +0.0%.
Free cash flow is USD -79.45M, negative for the stored period.
The balance sheet shows USD 93.97M of cash versus USD 38M of total debt, an excess of cash over debt on these two reported measures.
The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

Free cash flow is -114.0% of stored revenue. This is a simple cross-field ratio, not a verified same-period cash conversion margin; confirm reporting periods before comparison.
Net income equals -153.8% of stored revenue. This is an indicative ratio only; accounting periods and units should be verified in filings.
Cash exceeds debt by USD 55.97M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for PSNL

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

Can PSNL maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
How long can PSNL fund negative free cash flow using its current cash position before it may need more debt or new shares?
How is PSNL likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
What specifically needs to improve for PSNL to reach sustainable profitability?
What future growth or profitability would be needed to justify PSNL's current valuation?

What the numbers mean

Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.

The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-15.

Research-input completeness: 100% of the scoring inputs required for this public page are currently available.

How to research PSNL

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.